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ABSTRACT
Twenty-four hepatitis C virus patients coinfected with human T-lymphotropic virus type 1 were compared with six coinfected with HTLV-2 and 55 with 
HCV alone, regarding clinical, epidemiological, laboratory and histopathological data. Fischer’s discriminant analysis was applied to define functions 
capable of differentiating between the study groups (HCV, HCV/HTLV-1 and HCV/HTLV-2). The discriminant accuracy was evaluated by cross-validation. 
Alcohol consumption, use of intravenous drugs or inhaled cocaine and sexual partnership with intravenous drug users were more frequent in the 
HCV/HTLV-2 group, whereas patients in the HCV group more often reported abdominal pain or a sexual partner with hepatitis. Coinfected patients 
presented higher platelet counts, but aminotransferase and gamma-glutamyl transpeptidase levels were higher among HCV-infected subjects. No 
significant difference between the groups was seen regarding liver histopathological findings. Through discriminant analysis, classification functions 
were defined, including sex, age group, intravenous drug use and sexual partner with hepatitis. Cross-validation revealed high discriminant accuracy 
for the HCV group. 
Key-words: Hepatitis C virus. Human T-lymphotropic virus type 1. Human T-lymphotropic virus type 2. Epidemiological studies. 
Discriminant analysis. 
RESUMO
Compararam-se 24 pacientes coinfectados pelos vírus da hepatite C/vírus linfotrópico de células T humanas do tipo 1 com 6 coinfectados por VHC/
HTLV-2 e 55 infectados pelo VHC, no tocante a dados clínico-epidemiológicos, laboratoriais e histopatológicos. A análise discriminante de Fischer foi 
utilizada para definir funções capazes de diferenciar os grupos de estudo (VHC, VHC/HTLV-1 e VHC/HTLV-2). A acurácia discriminatória foi avaliada 
pelo por validação cruzada. O uso de álcool, drogas endovenosas, cocaína inalatória e a parceria sexual com UDEV foram mais freqüentes no grupo 
VHC/HTLV-2, enquanto queixa de dor abdominal e parceiro sexual com hepatite predominaram no grupo VHC. Os coinfectados apresentaram número 
maior de plaquetas, enquanto as aminotransferases e a gamaglutamiltranspeptidase foram mais altas no grupo VHC. Não houve diferença entre os 
grupos à análise histopatológica do fígado. Por análise discriminante definiram-se funções classificatórias, incluindo as variáveis sexo, faixa etária, 
uso de drogas endovenosas e parceiro sexual com hepatite, com acurácia discriminante alta para o grupo VHC. 
Palavras-chaves: Vírus da hepatite C. Vírus linfotrópico de células T humanas do tipo 1. Vírus linfotrópico de células T humanas do tipo 2. 
Estudos epidemiológicos. Análise discriminante.
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Since hepatitis C virus (HCV) and human T-cell lymphotropic 
virus type 1 (HTLV-1) and type 2 (HTLV-2) share their transmission 
means, the occurrence of coinfections is expected in populations 
at higher risk of sexual or blood-borne viral acquisition. In fact, 
HCV/HTLV coinfections have been described as frequent among 
intravenous drug users (IDUs)24, hemophiliacs5 and individuals 
who report unsafe sexual practices28.
However, the epidemiological and clinical features of HCV/
HTLV coinfected individuals have been overlooked. In-depth 
investigation of these characteristics may reveal particularly 
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relevant information about the risk of viral acquisition, as well as 
about the pathogenetic impact of coinfection on HCV and/or HTLV-
associated disease development. So far, virus-host interactions 
in coinfected individuals have been reported to be associated 
with dysfunctional cell immune response, which might impair 
HCV clearance and lead to accelerated progression of HCV liver 
disease12 27 29.  
To improve our understanding of HCV/HTLV-1 and HCV/HTLV-2 
coinfections, in the present study we compared sociodemographic 
features, variables relating to exposure to these viral infections, 
clinical and laboratory abnormalities, and liver histological 
characteristics among three groups of patients: HCV-infected 
individuals and HCV infected individuals presenting coinfection 
with either HTLV-1 or HTLV-2.
MATERIAL AND METHODS
Patient selection. For this cross-sectional study, we selected 
patients who were seen at specialized outpatient services that 
provide counseling and follow-up care for HCV and HTLV patients 
at Hospital das Clinicas, School of Medicine, University of São 
Paulo, between January 1993 and August 2005. For the HCV/HTLV-
1 and HCV/HTLV-2 groups, we enrolled adults who were diagnosed 
as HCV/HTLV-1 or HCV/HTLV-2 coinfected, respectively. The HCV 
group consisted of HCV-infected patients who presented neither 
HTLV-1 nor HTLV-2 infection. Patients with serological biomarkers 
indicating previous hepatitis B virus (HBV) infection, HIV 
coinfected individuals and transplant recipients were excluded.
The diagnosis of HCV infection was based on the seroreactivity 
of third-generation enzyme immunoassays (Murex Biotech, Baijing 
United Biomedical, and Embrabio, Brazil), followed by detection 
of HCV-RNA by means of nested RT-PCR amplification on a second 
plasma sample. The tests were performed in accordance with 
the manufacturers’ instructions, or as previously described15 16. 
A serodiagnosis of HTLV infection was established whenever 
seroreactivity was demonstrated using the commercially available 
enzyme immunoassays (Organon Technika, USA; Embrabio, 
Brazil), and was confirmed using Western blot tests (WB 2.3; 
WB 2.4, Diagnostic Biotechnology, Singapore), following the 
manufacturers’ instructions. Based on reactivity to type-specific 
recombinant peptides encoded by the gag and env regions of 
the HTLV proviral genome, the patients were discriminated as 
presenting either HTLV-1 or HTLV-2 infection, as recommended 
by the Brazilian Ministry of Health23. HTLV infection was further 
confirmed by nested PCR amplification of tax sequences of the 
proviral DNA from peripheral blood mononuclear cells (PBMC), 
as previously described17 18 37.
For the histopathological evaluation, patients were eligible 
only if their liver biopsy specimen was considered suitable for 
grading and staging tissue abnormalities8.
Study procedures. Patients were invited to take part in the 
survey at their regular medical follow-up visits to the outpatient 
clinic, between 2004 and 2006. Alternatively, those who did not 
attend the clinic during this period were contacted by telephone. 
If the patients agreed to participate, they were admitted to the 
study after giving their written consent. They then underwent a 
standardized interview with the research team, for epidemiological 
and clinical data to be obtained. In addition, the medical files were 
reviewed to collect laboratory and liver histopathological data. 
For analytical purposes, we used the results from hematological 
and liver function tests that had been performed less than 60 days 
before the liver biopsy procedure and before any therapeutic 
intervention for HCV liver disease. Throughout the data collection, 
confidentiality and patients’ anonymity were ensured. The study 
protocol was approved by the institutional review board.
The variables of interest included: 
	 sociodemographic characteristics: gender, age, skin color, 
marital status, schooling and place of birth; 
	 habits: smoking and alcohol consumption; 
	 risk factors for acquisition of sexually-transmitted or blood-
borne infections: history of intravenous drug use, history of 
inhaled cocaine use, history of blood transfusion, tattooing, 
acupuncture, sexual partnership with an IDU or with someone 
who reported hepatitis, and number of sexual partners in the 
year preceding admission to the study; 
	 clinical data: signs and symptoms of liver disease (jaundice, 
ascites, epistaxis, palmar erythema and spiders), malaise, 
abdominal pain, skin abnormalities, neurological symptoms 
(paresis and paresthesia), hepatomegaly or splenomegaly on 
clinical examination; 
	 results from laboratory tests: hemoglobin, hematocrit, white 
cell and platelet counts, serum liver enzyme concentrations 
(AST, ALT and GGT), alkaline phosphatase, serum bilirubin, 
albumin and gamma globulin concentrations and prothrombin 
time.
With regard to liver histopathological features, the data 
collection was based on a standardized review of all biopsy 
specimens. This was carried out by a single skilled professional, 
using Ishak’s diagnostic criteria19.
Statistical analysis. After setting up a database using the 
Microsoft Excel 2002 software, the patients in the different study 
groups (HCV/HTLV-1, HCV/HTLV-2 and HCV) were initially compared 
by means of bivariate analysis. The χ2 test was used to compare 
the proportions of individuals with variables of interest among 
the different study groups and the Kruskal-Wallis tests was used 
to compare continuous variables1 9. Subsequently, Fischer’s linear 
discriminant analysis was carried out to define classifying functions 
containing the variable set that together would best distinguish the 
patients in the three study groups20. Variables that exhibited p-values 
< 0.20 in bivariate analysis were chosen for multivariate analysis; age 
and gender were additionally included. The evaluation of the model’s 
discriminating accuracy was then checked by cross-validation, 
using the leave-one-out technique7 10. In this procedure, each study 
subject was analyzed as external to the model and was classified 
again by applying his/her data to the new classifying functions 
that had been set up using the other (n-1) study subjects. The 
discriminating accuracy of the model was considered high when 
the cross-validation procedure yielded the right classification 
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in more than 75% of the cases10. The statistical analysis was 
performed using the SPSS version 13.0 software package, with a 
5% significance level.
RESULTS
The study cohort comprised 85 patients, diagnosed as 
follows: 24 (28.3%) HCV/HTLV-1 coinfected individuals, 6 (7%) 
with HCV/HTLV-2 coinfection and 55 (64.7%) infected with HCV 
alone. Most (53%) patients were male and aged from 20 to 59 
(mean age, 40). White (71.8%) and married (51.8%) subjects, 
with eight to ten years of schooling (45.9%), born in the State 
of São Paulo (71.8%), predominated (Table 1). With regard to 
TABLE 1
Comparison of 24 HCV/HTLV-1 coinfected, six HCV/HTLV 2 coinfected and 55 HCV-
infected patients with regard to sociodemographic features. Hospital das Clinicas, 
School of Medicine, University of São Paulo, 1993-2005.
            Group 
                         HCV       HCV/HTLV-1         HCV/HTLV-2 
Variable n % n % n % P
Gender       0.98
male 29  52.7 13  54.2 3 50.0 
female 26  47.3 11  45.8 3 50.0 
Age (years)       0.18
18 - 29 17  30.9 5  20.8 1 16.7 
30 - 39 9  16.4 6  25.0 4 66.6 
40 - 49 19  34.5 9  37.5 1 16.7 
> 50  10  18.2 4  16.7 - - 
Color       0.50
white  39  70.9 17  70.8 5 83.3 
mulatto 13  23.6 3  12.5 1 16.7 
black 3  5.5 3  12.5 - - 
yellow      -    - 1  4.2 - - 
Marital status       0,59
married 30 54.5 10  41.6 4 66.6 
single 14  25.5 9  37.5 1 16.7 
divorced 11  20.0 4  16.7 1 16.7 
widowed     -   - 1  4.2 - - 
Schooling (years)       0.56
< 7 19  34.5 6  25.0 1 16.7 
8 - 10 22  40.0 14 58.3 3 50.0 
> 11 14  25.5 4  16.7 2 33.3 
State of birth       0.08
São Paulo 35  63.6 21  87.5 5 83.3 
others 20  36.4 3  12.5 1 16.7 
Smoking*       0.179
no 38 70.4 12 50.0 3 50.0 
yes 16 29.6 12 50.0 3 50.0 
Alcohol consumption       0.009
no 40 72.7 12 50.0 1 16.7 
yes 15 27.3 12 50.0 5 83.3 
*data missing for one patient from the HCV group 
HCV: hepatitis C virus, HTLV-1: human T-lymphotropic virus type 1, HTLV-2: human 
T-lymphotropic virus type 2.
smoking, no statistically significant difference was seen among 
the study groups. In contrast, reported alcohol consumption was 
significantly more frequent among the patients in the HCV/HTLV-2 
group (p = 0.009).
Table 2 summarizes the exposure to sexually-transmitted or 
blood-borne infections among the patients in the different study 
groups. Reported intravenous drug use, inhaled cocaine use and 
sexual partnership with an IDU were significantly more frequent 
among the patients in the HCV/HTLV-2 group, compared with the 
other groups. Sexual partnership with an individual with hepatitis, 
however, was more often seen in the HCV group.
Regarding clinical complaints, abdominal pain was reported 
more frequently by the patients in the HCV group (25.5%, 
p = 0.024), compared with 16.7% of their counterparts in the 
HCV/HTLV-2 group and none of the patients with HCV/HTLV-1 
coinfection. No significant differences were noticed among the 
TABLE 2
Comparison of 24 HCV/HTLV-1 coinfected, six HCV/HTLV 2 coinfected and 55 HCV-
infected patients with regard to risk factors for virus acquisition. Hospital das Clinicas, 
School of Medicine, University of São Paulo, 1993-2005.
                                                             Group 
                                       HCV            HCV/HTLV-1  HCV/HTLV-2 
Variable  n % n % n %  P
Intravenous drug use        <0.001
no 53 96.4 20 83.3 2 33.3 
yes 2 3.6 4 16.7 4 66.7 
Inhaled cocaine use        0.022
no 41 74.5 21 87.5 2 33.3 
yes 14 25.5 3 12.5 4 66.7 
Sexual partnership with IDU*       <0.001
no 53 96.4 17 77.3 -  - 
yes 2 3.6 5 22.7 3 100.0 
Sexual partner with hepatitis**       0.001
no 50 90.9 16 94.1 4 100.0 
yes 5 9.1 1 5.9 -  - 
Recipient of blood transfusion       0.332
no 32 58.2 12 50.0 5 83.3 
yes 23 41.8 12 50.0 1 16.7 
Tattooing       0.061
no 51 92.7 23 95.8 4 66.7 
yes 4 7.3 1 4.2 2 33.3 
Acupuncture       0.349
no 48 87.3 23 95.8 6 100.0 
yes 7 12.7 1 4.2 -  - 
Number of sexual partners 
in the previous year***       0.224
1 50 92.6 19 79.2 5 83.3 
> 1 4 7.4 5 20.8 1 16.7 
*data missing for 7 and 2 patients from the HCV/HTLV-1 and HCV/HTLV-2 groups, 
respectively.
**data missing for 2 and 3 patients from the HCV/HTLV-1 and HCV/HTLV-2 groups, 
respectively.
***data missing for one patient from the HCV group
HCV: hepatitis C virus, HTLV-1: human T-lymphotropic virus type 1, HTLV-2: human 
T-lymphotropic virus type 2, IDU: intravenous drug user.
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study groups regarding the frequency of signs and symptoms 
of liver disease (jaundice, ascites, epistaxis, palmar erythema, 
spiders, hepatomegaly or splenomegaly), reported malaise or skin 
and neurological abnormalities on clinical examination.
Laboratory investigations yielded significantly higher median 
platelet counts in HCV/HTLV-1 or HCV/HTLV-2 coinfected 
individuals, compared with patients in the HCV group (p = 0.015). 
Conversely, higher median serum AST, ALT and GGT concentrations 
were seen in HCV-infected patients (p = 0.047, p = 0.011 and 
p < 0.001, respectively).
Seventy-five patients (88.2% of the study cohort) were 
compared regarding their liver histopathological features. 
Although most of them exhibited abnormal findings in their liver 
biopsy specimens, no statistically significant differences were seen 
among the patients in the different study groups (Table 3).
TABLE 3
Comparison of 24 HCV/HTLV-1 coinfected, six HCV/HTLV 2 coinfected and 55 HCV-
infected patients with regard to liver histopathological findings. Hospital das Clinicas, 
School of Medicine, University of São Paulo, 1993-2005.
    Group 
     HCV         HCV/HTLV-1  HCV/HTLV-2 
Variable n % n % n % P
Fibrosis (score)       0.763
< 3 37 67.3 11 68.8 2 50.0 
> 3 18 32.7   5 31.2 2 50.0 
Necroinflammatory activity (score)       0.256
minimal (0 - 6) 20 36.4   4 25.0 -    - 
mild/moderate ( 7 -12)  35 63.6 12 75.0 4 100.0 
Portal inflammation       
present (score > 1) 55 100.0 16 100.0 4 100.0 
Periportal or periseptal 
interface hepatitis       0.547
absent 18 32.7   3 18.8 1 25.0 
present 37 67.3 13 81.2 3 75.0 
Lobular necrosis       0.145
absent    1 1.8   2 12.5 -    - 
present 54 98.2 14 87.5 4 100 
After Fischer’s discriminant analysis, the following 
discriminating functions were defined for each of the study 
groups:
y
HCV
 = - 6.558 + 0.605 (IDU) + 0.045 (sexual partnership 
with someone with reported hepatitis) + 4.976 (gender) + 1.485 
(age group)
y
HCV/HTLV-1
 = - 7.178 + 1.636 (IDU) + 1.437 (sexual partnership 
with someone with reported hepatitis) + 4.942 (gender) + 1.512 
(age group)
y
HCV/HTLV-2
 = - 9.685 + 9.265 (IDU) + 0.849 (sexual partnership 
with someone with reported hepatitis) + 6.303 (gender) + 0.487 
(age group)
IDU (yes = 0, no = 1); sexual partnership with someone with reported hepatitis (yes 
= 0, no = 1); gender (male = 0, female = 1); age group (18 to 29 years = 0; 30 to 
39 years = 1; 40 to 49 years = 2; 50 years or more = 3)
Cross-validation of the model using the leave-one-out 
technique showed that even though the discriminating functions 
were able to classify 67.1% of the patients in the study cohort 
correctly, their performance differed in each of the three study 
groups. The discriminating accuracy was high (87.3%) for the 
HCV group-defining function, but intermediate (66.7%) for the 
HCV/HTLV-2 function. In contrast, the HCV/HTLV-1 group function 
exhibited low (20.8%) discriminating accuracy.
DISCUSSION
HCV/HTLV coinfections are a matter of particular concern 
with regard to the clinical management of patients with 
infectious diseases, not only because of the epidemiological 
importance of these viral infections in Brazil, but also because 
of the possible pathogenetic interactions among them. However, 
the epidemiological, clinical and laboratory features of these 
coinfections have been overlooked so far, or alternatively, have 
been investigated without clear distinction of the HTLV type (HTLV-
1 or HTLV-2) that is involved. By means of Fischer’s discriminating 
analysis, our study investigated epidemiological, clinical and 
laboratory diagnostic tools that might better differentiate HCV/HTLV 
coinfected individuals from their HCV-infected counterparts. 
Among the variables that were defined as useful for 
discriminating between coinfected individuals, self-reporting of 
intravenous drug use was particularly relevant. It was more often 
found among HCV/HTLV-2 coinfected patients, thus suggesting 
that this route was important for acquisition of this retrovirus 
among the study population, as previously reported in other 
epidemiological contexts. De la Fuente et al. found that HTLV-2 
infection was strongly associated with injectable drug use among 
young Spanish addicts, as well as with HIV and HCV coinfections13. 
Likewise, in a prevalence study on HTLV infection among American 
women, HTLV-2 infection was shown to be significantly associated 
with injectable drug use, regardless of HIV coinfection36. 
Nonetheless, previous Brazilian studies presented conflicting data 
with regard to the association between intravenous drug use and 
HTLV-2 infection. Although some investigators have indicated an 
epidemiologic association14, studies conducted more recently 
have highlighted the leading role of HTLV-1 among HTLV-infected 
drug addicts in Bahia11. Our results reinforce the idea that HTLV-2 
infection is possibly spread by means of injectable drug use, and 
thus suggest that the way in which this retrovirus circulates may 
vary between different Brazilian geographic regions. 
Regarding sexual activity, we found that the patients in the 
different study groups differed in their reports about having a 
sexual partner with hepatitis. Since the role of sexual transmission 
in the epidemiology of HCV infection is still controversial34, we 
hypothesize that the routine counseling that was provided for 
individuals with HTLV, to encourage them to adopt safer sexual 
practices6 23, may have accounted for the observed difference, to 
a certain extent. Sexual partnership with an IDU was significantly 
more frequent among the patients in the HCV/HTLV-2 group, thus 
suggesting that they were at greater risk of HTLV-2 acquisition 
through sexual means. However, even though HTLV-1 and 
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HTLV-2 have been acknowledged to be sexually-transmitted 
agents26 35 38, recent evidence has suggested that transmission is not 
particularly associated with any of the HTLV types30. Alternatively, 
and speculatively, the increased risk of HTLV-2 acquisition among 
these individuals may have been due to non-reported IDU, as 
previously described in a serological survey of HCV coinfection 
among people living with HIV in Santos, Brazil34.
Use of inhaled cocaine was significantly more often reported 
among the patients in the HCV/HTLV-2 group. Nevertheless, since 
there is no evidence that such practices add to the risk of HTLV-2 
acquisition, and because no information was available about the 
sharing of instruments for inhalation21, we believe that this might 
be a confounder. Based on reports in the literature that indicate 
that alcohol consumption is high among intravenous drug users2, 
we suppose that this association may have contributed towards 
our finding of a higher frequency of alcohol consumption among 
HCV/HTLV-2 coinfected individuals from our cohort. 
The chronic course of HCV infection, as well as the fact 
that HTLV infection is most often asymptomatic throughout life, 
may have impaired the statistical power of the clinical variables 
regarding their ability to differentiate patients in the different study 
groups, except for abdominal pain. This complaint was more often 
reported by patients in the HCV group. Although this symptom is 
frequently reported by HCV-infected individuals22, pathogenetic 
mechanisms that might justify different frequencies of abdominal 
pain between HCV-infected and HCV/HTLV coinfected patients 
could not be identified.
Laboratory investigations demonstrated lower platelet counts 
among the HCV-infected patients, compared with the coinfected 
individuals. In contrast, although the aminotransferase and 
GGT levels were high in patients in all of the groups, they were 
significantly higher in the HCV group. This discrepancy might 
be due to HCV disease that was more advanced. Nevertheless, 
this was not supported by histopathological data. Alternatively, 
differences in platelet counts could be ascribed to HTLV-driven 
thrombocytogenesis, as hypothesized by Murphy et al25 from an 
evaluation on hematological disorders among asymptomatic 
carriers of retroviral infection who were volunteer blood donors 
at different centers in the USA. 
In our study, the analysis of liver histopathological 
abnormalities revealed higher frequencies of less severe fibrosis 
(score < 3) among the HCV (67.3%) and HCV/HTLV-1 (68.8%) 
individuals, compared with the HCV/HTLV-2 individuals (50%), 
although without statistical significance. Although length of time 
since HCV infection and age at the first biopsy procedure have been 
recognized as associated with progression of HCV-related fibrosis3 31, 
these variables were not useful for clarifying differences in the 
histopathological data in our study. We found no significant age 
differences among the patients in the different study groups at 
the time when they underwent liver biopsy. Moreover, the cross-
sectional design of our study precluded recognition of length of 
time with HCV infection and of the precise chronology of events 
among coinfected HCV/HTLV individuals. In contrast to these 
methodological constraints, Japanese longitudinal studies have 
provided evidence of accelerated HCV disease progression among 
HCV/HTLV-1 coinfected patients4. Follow-up of our patients, with 
inclusion of more HCV/HTLV-2 individuals, is thus warranted in 
order to clarify the impact of HTLV coinfection on the progression 
of HCV disease.
Another limitation of our study resulted from the fact that there 
were few HCV/HTLV coinfected individuals among the patients 
seen at the clinic, who were not also HBV or HIV-coinfected32 33. 
Since these viruses share their means of transmission, multiple 
coinfections are often identified among individuals at high risk 
of viral exposure.
Despite these limitations, we believe our study has improved 
the understanding of the epidemiological, clinical, laboratory 
and histopathological features of HCV/HTLV coinfection and has 
contributed towards better identification of distinctive features for 
discriminating between HCV-infected and HCV/HTLV coinfected 
individuals. Applying this information to the routine care of HCV-
infected patients may help the healthcare team clarify when HTLV 
serological screening and counseling should be implemented for 
these individuals. 
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